IFNG and neoplasm: TC-1 tumor-bearing mice were treated with various combinations of cisplatin, CpG and PADRE peptide as shown in Fig. 1A and PBMCs were analyzed by flow cytometry 1 week after the last antigen delivery for the presence of IFN-γ secreting PADRE-specific CD4+ T cells.